Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer

Cancer Letters

Volumn 191, Issue 2, 2003, Pages 229-237

  Wang, Hsien Yu ^a   Cheng, Zhiyong ^a   Malbon, Craig C ^a  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

c Jun N terminal kinase; Human breast cancer; Mitogen activated protein kinases; Mitogen activate protein kinase phosphatases 1 and 2; P38

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN SUBUNIT; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN;

ADULT; APOPTOSIS; ARTICLE; BREAST; BREAST CANCER; CANCER CELL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME REPRESSION; EPITHELIUM; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STAINING; UPREGULATION;

EID: 0037430452     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00612-2     Document Type: Article

References (34)

1. Whitmarsh A.J., Davis R.J. Signal transduction by MAP kinases: regulation by phosphorylationdependent switches. Sci. STKE. (1999):1999;E1.
2. Schlesinger T.K., Fanger G.R., Yujiri T., Johnson G.L. The TAO of MEKK. Front. Biosci. 3:1998;D1181-D1186.
3. Sivaraman V.S., Wang H., Nuovo G.J., Malbon C.C. Hyperexpression of mitogen-activated protein kinase in human breast cancer (see comments). J. Clin. Invest. 99:1997;1478-1483.
4. Oka H., Chatani Y., Hoshino R., Ogawa O., Kakehi Y., Terachi T., Okada Y., Kawaichi M., Kohno M., Yoshida O. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 55:1995;4182-4187.
5. Johnson G.L. Signal transduction abnormalities in cancer mitogen-activated protein kinase regulation is altered in breast cancer. J. Clin. lnvest. 99:1997;1463-1464.
6. Koo H.M., VanBrocklin M., McWilliams M.J., Leppla S.H., Duesbery N.S., Woude G.F. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc. Natl. Acad. Sci. USA. 99:2002;3052-3057.
7. Kim S.C., Hahn J.S., Min Y.H., Yoo N.C., Ko Y.W., Lee W.J. Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1. Blood. 93:1999;3893-3899.
8. Xing C., Imagawa W. Altered MAP kinase (ERK1,2) regulation in primary cultures of mammary tumor cells: elevated basal activity and sustained response to EGF. Carcinogenesis. 20:1999;1201-1208.
9. Mandell J.W., Hussaini I.M., Zecevic M., Weber M.J., VandenBerg S.R. In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am. J. Pathol. 153:1998;1411-1423.
10. Barry O.P., Mullan B., Sheehan D., Kazanietz M.G., Shanahan F., Collins J.K., O'Sullivan G.C. Constitutive ERK1/2 activation in esophagogastric rib bone marrow micrometastatic cells is MEK-independent. J. Biol. Chem. 276:2001;15537-15546.
11. Santen R.J., Song R.X., McPherson R., Kumar R., Adam L., Jeng M.H., Yue W. The role of mitogen-activated protein (MAP) kinase in breast cancer. J. Steroid Biochem. Mol. Biol. 80:2002;239-256.
12. Hori M., Inagawa S., Shimazaki J., Itabashi M., Hori M. Overexpression of mitogen-activated protein kinase superfamily proteins unrelated to Ras and AF-1 of estrogen receptor alpha mutation in advanced stage human breast cancer. Pathol., Res. Practice. 196:2000;817-826.
13. Esteva F.J., Hortobagyi G.N., Sahin A.A., Smith T.L., Chin D.M., Liang S.Y., Pusztai L., Buzdar A.U., Bacus S.S. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry, Pathol. Oncol. Res. 7:2001;171-177.
14. Gioeli D., Mandell J.W., Petroni G.R., Frierson H.F. Jr., Weber M.J. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 59:1999;279-284.
15. Damodar R.C., Marwaha S., Patti R., Raghunath M., Duhaime A.C., Sutton L., Phillips P.C. Role of MAP kinase pathways in primitive neuroectodermal tumors. Anticancer Res. 21:2001;2733-2738.
16. Albanell J., Codony-Servat J., Rojo F., Del Campo J.M., Sauleda S., Anido J., Raspall G., Giralt J., Rosello J., Nicholson R.I., Mendelsohn J., Baselga J. Activated extracellular signal-regulated kinases: association with epidemial growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res. 61:2001;6500-6510.
17. Ito Y., Sasaki Y., Horimoto M., Wada S., Tanaka Y., Kasahara A., Ueki T., Hirano T., Yamamoto H., Fujimoto J., Okamoto E., Hayashi N., Hori M. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology. 27:1998;951-958.
18. Price D.T., Rocca G.D., Guo C., Ballo M.S., Schwinn D.A., Luttrell L.M. Activation of extracellular signal-regulated kinase in human prostate cancer. J. Urol. 162:1999;1537-1542.
19. Yu W., Liao Q.Y., Hantash F.M., Sanders B.G., Kline K. Activation of extracellular signal-regulated kinase and c-Jun-NH(2)-terminal kinase but not p38 mitogen-activated protein kinases is required for RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells. Cancer Res. 61:2001;6569-6576.
20. Hermanto U., Zong C.S., Wang L.H. Inhibition of mitogen-activated protein kinase kinase selectively inhibits cell proliferation in human breast cancer cells displaying enhanced insulin-like growth factor I- mediated mitogen-activated protein kinase activation. Cell Growth Differ. 11:2000;655-664.
21. Krueger J.S., Keshamouni V.G., Atanaskova N., Reddy K.B. Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene. 20:2001;4209-4218.
22. Fan M., Chambers T.C. Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist. Updat. 4:2001;253-267.
23. Moxham C.M., Tabrizchi A., Davis R.J., Malbon C.C. Jun N-terminal kinase mediates activation of skeletal muscle glycogen synthase by insulin in vivo. J. Biol. Chem. 271:1996;30765-30773.
24. Ros M., Northup J.K., Malbon C.C. Steady-state levels of G-proteins and beta-adrenergic receptors in rat fat cells: permissive effects of thyroid hormones. J. Biol. Chem. 263:1988;4362-4368.
25. Gioeli D., Mandell J.W., Petroni G.R., Frierson H.F. Jr., Weber M.J. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 59:1999;279-284.
26. Salh B., Marotta A., Wagey R., Sayed M., Pelech S. Dysregulation of phosphatidylinositol 3-kinase and downstream effectors in human breast cancer. Int. J. Cancer. 98:2002;148-154.
27. Greenberg A.K., Basu S., Hu J., Yie T.A., Tchou-Wong K.M., Rom W.N., Lee T.C. Selective p38 activation in human non-small cell lung cancer. Am. J. Respir. Cell Mol. Biol. 26:2002;558-564.
28. Weston C.R., Davis R.J. The JNK signal transduction pathway. Curr. Opin. Genet. Dev. 12:2002;14-21.
29. lp Y.T., Davis R.J. Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammation to development. Curr. Opin. Cell Biol. 10:1998;205-219.
30. Gee J.M., Barroso A.F., Ellis I.O., Robertson J.F., Nicholson R.I. Biological and clinical associations of c-jun activation in human breast cancer. Int. J. Cancer. 89:2000;177-186.
31. Harding T.C., Xue L., Bienemann A., Haywood D., Dickens M., Tolkovsky A.M., Uney J.B. Inhibition of JNK by overexpression of the JNL binding domain of JIP-1 prevents apoptosis in sympathetic neurons. J. Biol. Chem. 276:2001;4531-4534.
32. Yasuda J., Whitmarsh A.J., Cavanagh J., Sharma M., Davis R.J. The JIP group of mitogen-activated protein kinase scaffold proteins. Mol. Cell Biol. 19:1999;7245-7254.
33. Pavelic K., Gall-Troselj K. Recent advances in molecular genetics of breast cancer. J. Mol. Med. 79:2001;566-573.
34. Lee J.T. Jr., McCubrey J.A. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia. 16:2002;486-507.